RaeSedo
RaeSedo, Inc. is dedicated to developing a new class of asthma therapeutics based on peptides derived from surfactant protein-A (SP-A), an innate immune modulator in the lungs. The company aims to create stable, inhaled peptidomimetics that mimic the activity of endogenous SP-A to reduce inflammation and improve outcomes for asthma and other lung diseases. Founded by women physician-scientists, RaeSedo leverages extensive NIH funding and collaborations with the University of Arizona to translate scientific discoveries into innovative treatments.
Industries
Nr. of Employees
small (1-50)
Products
SP-A-derived peptidomimetic inhaled therapeutic candidates (short peptides <20 AA)
Short synthetic peptides derived from active regions of an endogenous surfactant protein, formulated for inhalation to reduce airway inflammation, mucus production and airway hyperresponsiveness in asthma and related inflammatory lung diseases.
SP-A-derived peptidomimetic inhaled therapeutic candidates (short peptides <20 AA)
Short synthetic peptides derived from active regions of an endogenous surfactant protein, formulated for inhalation to reduce airway inflammation, mucus production and airway hyperresponsiveness in asthma and related inflammatory lung diseases.
Services
Management and deployment of university-origin intellectual property and coordination of collaborative research/subcontracts to advance preclinical candidates.
Management and deployment of university-origin intellectual property and coordination of collaborative research/subcontracts to advance preclinical candidates.
Expertise Areas
- Peptidomimetic therapeutic discovery
- Pulmonary/inhalation drug development
- Preclinical asthma and airway disease models
- Peptide synthesis and combinatorial chemistry
Key Technologies
- Peptidomimetics (short synthetic peptides)
- Combinatorial chemistry and library synthesis
- Peptide synthesis and purification
- Aerosol/inhalation delivery systems